Monitoring dan Evaluasi

Rekrutment Peserta PRB Tahun

2022 di FKRTL
KC JAKSEL

Batch I
Jakarta, 22 July 2022

1
 Pokok-Pokok Materi

Alur PRB

Identifikasi potensi PRB di RS

Tugas dan kriteria PIC PRB

Kriteria Stabil 9 Diagnosa PRB

Feedback Rujukan Internal

2
Pelayanan Rujuk balik adalah Pelayanan kesehatan yang diberikan kepada penderita
di Fasilitas Kesehatan atas rekomendasi/rujukan dari Dokter Spesialis/Sub Spesialis yang
merawat.

Pelayanan Program Rujuk Balik adalah Pelayanan Kesehatan yang diberikan kepada
penderita penyakit kronis dengan kondisi stabil dan masih memerlukan pengobatan
atau asuhan keperawatan jangka panjang yang dilaksanakan di Faskes Tingkat Pertama
atas rekomendasi/rujukan dari Dokter Spesialis/Sub Spesialis yang merawat.

A. JENIS PENYAKIT (SESUAI DENGAN SE MENKES HK/MENKES/31/I/2014)

1.DIABETES MELLITUS 6. EPILEPSI
2.HIPERTENSI 7. SCHIZOPHRENIA
3.JANTUNG 8. STROKE
4.ASTMA 9. SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
5.PPOK

3
 OBAT PROGRAM RUJUK BALIK (PRB)

obat yang diresepkan oleh Dokter Spesialis/Sub

Obat Utama Spesialis di FKRTL untuk indikasi yang sesuai dengan
diagnosis PRB
Obat PRB
obat yang dapat diberikan bersama obat utama
Obat untuk mengatasi penyakit penyerta atau
Tambahan mengurangi efek samping akibat obat utama

 Peresepan obat PRB maksimal untuk kebutuhan 30 (tiga puluh) hari sesuai indikasi
medis.
 Peresepan obat PRB, baik obat utama dan obat tambahan, mengacu pada
Formularium Nasional (Fornas) untuk obat PRB (obat bertanda asterix*)
berikut restriksi, peresepan maksimal dan ketentuan lainnya yang berlaku;
 Obat diluar Fornas, termasuk obat yang tidak sesuai dengan ketentuan Fornas
(tidak
sesuai restriksi dan peresepan maksimal) tidak dapat diberikan kepada Peserta
PRB
 pemberian obat mengikuti mekanisme pemberian obat di luar Fornas dan
biaya termasuk dalam paket INA CBG.
IDENTIFIKASI FLAGGING PESERTA PRB

NOTIFIKASI POTENSI PRB DI LEMBAR SEP

PENYAKIT KRONIS DENGAN KUNJUNGAN

BERULANG 3 BULAN TANPA TAMBAHAN TERAPI

3B:
BENAR DIAGNOSA NYA (MASUK DALAM 9 DIAGNOSA PRB)
BENAR OBATNYA (MASUK DALAM DAFTAR OBAT PRB DALAM
FORNAS)
BENAR STABIL (SESUAI KRITERIA STABIL)
5
 Identifikasi Potensi PRB di RS
• Potensi PRB adalah kunjungan berulang /kunjungan
Kontrol/Rujukan Internal
Grafik 4 Pintu RJTL sd Juni 2022

6
ALUR PELAYANAN PROGRAM RUJUK BALIK (PRB) DI FKRTL
 Alur Flagging Peserta PRB di FKRTL

SRB IFRS memberikan

Obat 7 hari
Resep 7 hari

Petugas RS Peserta diminta ke FKTP

Peserta Selesai dari
melakukan Flagging Di untuk obat 23 hari
PoliKlinik
V-Claim
Pelayanan Poliklinik
1. Dokter menetapkan kondisi stabil pada
pasien penyakit kronis
P-Care
2. Dokter menuliskan SRB Dokter FKTP menuliskan resep
3. Dokter memberikan resep sesuai ketentuan atau mempersuasi potensi PRB
Fornas untuk PRB

Data
Potensi
PRB
Peserta dengan riwayat 3 bulan
diagnosa PRB dengan sediaan
obat yang sama Apotik Online Apotek PRB
memberikan Obat 23 hari dan MTM

Selanjutnya selama 3 bulan/selama peserta

setuju/kondisi baik peserta mengambil obat
Alur Pelayanan

Alur Integrasi Data

 Tugas dan Kriteria PIC PRB
Memiliki pengetahuan mengenai program PRB dan alur PRB

Bersedia dan beromitmen untuk menjalankan Program Rujuk Balik.

Dapat mengidentifikasi potensi PRB secara mandiri.

Berperan aktif dan melaksanakan monitoring bersama secara berkala PIC

PRB dan Tim

Bersedia melaksanakan Implementasi Improvement PRB di RS seperti :

Pemanfaatan Pojok PRB, Penggunaan leaflet dan kalender PRB secara optimal.

SK PIC PRB MASUK DALAM DOKUMEN KELENGKAPAN KREDENSIALING PKS

9
 REKOMENDASI ORGANISASI (IDI & PERHIMPUNAN TERKAIT)
KRITERIA STABIL 9 KASUS PRB
1. EPILEPSI REKOMENDASI PERDOSSI

2. STROKE REKOMENDASI PERDOSSI

3. PENYAKIT JANTUNG
REKOMENDASI PAPDI DAN PERKI
HIPERTENSI

INFARK MIOKARDIUM REKOMENDASI PERKI DAN PAPDI

ANGINA
REKOMENDASI PERKI DAN PAPDI
PEKTORALIS
STABIL

GAGAL JANTUNG KRONIK REKOMENDASI PERKI DAN PAPDI

4. DIABETES MELITUS REKOMENDASI PAPDI DAN PERKENI
5. HIPERTENSI REKOMENDASI PAPDI, PERHI, PERNEFRI

6. ASMA REKOMENDASI PAPDI DAN PDPI

 REKOMENDASI ORGANISASI (IDI & PERHIMPUNAN TERKAIT)

KRITERIA STABIL 9 KASUS PRB

7. PPOK REKOMENDASI PAPDI DAN PDPI

8. SKIZOFRENIA REKOMENDASI PDSKJI

9. SLE PAPDI
 FKRTL DENGAN GAP CAPAIAN REKRUTMEN PESERTA PRB TERBESAR

No NAMA FASKES TARGET TARGET TARGET Jan-22 Feb-22 Mar-22 Apr-22 May-22 Jun-22 Juli-22 JUMLAH PRB GAP TARGET
TAHUN BULANAN MINGGUAN (s/d 18 TERDAFTAR 01 JAN HARIAN
2022 Juli 2022) SD 18 JULI 22
1 RS JAKARTA 40 3 1 0 0 1 2 0 0 0 3 37 1
2 RSUD KEBAYORAN LAMA 120 10 2 0 0 0 2 0 2 1 5 115 1
3 RS. Dr. Suyoto 16 1 0 0 0 3 1 0 0 0 4 12 1
4 RS KARTINI 16 1 0 1 1 2 2 0 1 2 9 7 1
5 RS TRIA DIPA 40 3 1 0 1 0 0 0 0 2 3 37 1

KENDALA IMPLEMENTASI DI
FKRTL ????

12
Kasus terbanyak dirawat Jalan adalah Penyakit Kronis Kecil Lain –Lain 
POTENSI PRB

Januari 2022 sd Mei 2022 13

Contoh kasus potensi Peserta untuk Rekrutmen
PRB
RS TRIA DIPA

14
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RS TRIA DIPA

15
Sasaran Rekrutmen PRB
RS Jakarta

PIC PRB FOKUS

PADA POLIKLINIK
SARAF?

16
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RS Jakarta

17
Sasaran Rekrutmen PRB
RSUD Kebayoran Lama

PIC PRB FOKUS

PADA POLIKLINIK
ANAK dan INTERNA?

18
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RSUD Kebayoran Lama
jenis PRB Nosjp Nokapst Kdppklayan Nmtkp Politujsjp Day of Tgldtgsjp
Day of Tglplgsjp
Kddiagprimer
Nmdiagprimer
DiagsekunderKlsrawat Procedure Namadpjp Kdinacbgs
DM 0112R0830322V000291
12121082 0112R083 RJTL INT 2022 3 22 2022 3 22 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications
SPPD
DM 0112R0830222V000270
12121082 0112R083 RJTL INT 2022 2 19 2022 2 19 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications
Q-5-44-0
PASHA
DM 0112R0830422V000162
16387762 0112R083 RJTL INT 2022 4 7 2022 4 7 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830522V000221
16387762 0112R083 RJTL INT 2022 5 11 2022 5 11 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830222V000235
22692013 0112R083 RJTL INT 2022 2 17 2022 2 17 R104 Other and unspecified
E119 - Non-insulin-dependent
abdominal
Kelas III pain
8876 - diabetes
Diagnostic
DR.mellitus
OLLIEN
ultrasound
without
Z-3-23-0
KARTIKA,
of complications
abdomen
SP.PD and retrope
DM 0112R0830222V000338
22692013 0112R083 RJTL INT 2022 2 24 2022 2 24 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000646
25491664 0112R083 RJTL INT 2022 1 22 2022 1 22 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications
Q-5-44-0
PASHA
DM 0112R0830222V000264
25491664 0112R083 RJTL INT 2022 2 19 2022 2 19 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications
Q-5-44-0
PASHA
DM 0112R0830522V000227
308038525 0112R083 RJTL INT 2022 5 11 2022 5 11 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000648
308038525 0112R083 RJTL INT 2022 1 22 2022 1 22 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications;I10
Q-5-44-0
PASHA - Essential (prim
DM 0112R0830322V000377
30836963 0112R083 RJTL INT 2022 3 24 2022 3 24 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830422V000621
30836963 0112R083 RJTL INT 2022 4 26 2022 4 26 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830522V000088
30836963 0112R083 RJTL INT 2022 5 6 2022 5 6 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830422V000537
312935758 0112R083 RJTL INT 2022 4 22 2022 4 22 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications
SPPD
DM 0112R0830222V000085
312935758 0112R083 RJTL SAR 2022 2 4 2022 2 4 Z033 ObservationE149
for suspected
- Unspecified
Kelas
nervous
IIIdiabetes
system
mellitus
disorder
DR.
without
NADIA
complications
HUSEIN,
Q-5-44-0 SP.S
DM 0112R0830322V000189
321687596 0112R083 RJTL INT 2022 3 16 2022 3 16 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830422V000477
321687596 0112R083 RJTL INT 2022 4 20 2022 4 20 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000469
321687596 0112R083 RJTL INT 2022 1 17 2022 1 17 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications
Q-5-44-0
PASHA
DM 0112R0830322V000211
366753811 0112R083 RJTL INT 2022 3 17 2022 3 17 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830522V000577
366753811 0112R083 RJTL INT 2022 5 24 2022 5 24 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000548
366753811 0112R083 RJTL INT 2022 1 19 2022 1 19 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications;I10
Q-5-44-0
PASHA - Essential (prim
DM 0112R0830222V000227
366753811 0112R083 RJTL INT 2022 2 16 2022 2 16 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications;I10
Q-5-44-0
PASHA - Essential (prim
DM 0112R0830422V000495
372391574 0112R083 RJTL INT 2022 4 21 2022 4 21 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830422V000649
372391574 0112R083 RJTL INT 2022 4 28 2022 4 28 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830522V000787
372391574 0112R083 RJTL INT 2022 5 31 2022 5 31 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830122V000810
37262660 0112R083 RJTL INT 2022 1 27 2022 1 27 E119 Non-insulin-dependent
I10 - Essential
diabetes
Kelas
(primary)
III mellitus
hypertension
without DR.
complications
OLLIENQ-5-44-0
KARTIKA, SP.PD
DM 0112R0830522V000582
37262660 0112R083 RJTL INT 2022 5 24 2022 5 24 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000706
424336338 0112R083 RJTL INT 2022 1 25 2022 1 25 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications
SP.PD
DM 0112R0830422V000539
424336338 0112R083 RJTL INT 2022 4 22 2022 4 22 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications
SPPD
DM 0112R0830422V000095
44223978 0112R083 RJTL INT 2022 4 5 2022 4 5 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000112
44223978 0112R083 RJTL INT 2022 1 5 2022 1 5 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications
Q-5-44-0
PASHA
DM 0112R0830222V000032
44223978 0112R083 RJTL INT 2022 2 2 2022 2 2 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
MUHAMMAD
conditions
complications;I10
Q-5-44-0
PASHA - Essential (prim
DM 0112R0830322V000089
44282682 0112R083 RJTL INT 2022 3 8 2022 3 8 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830422V000357
44282682 0112R083 RJTL INT 2022 4 14 2022 4 14 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830422V000349
45211593 0112R083 RJTL INT 2022 4 14 2022 4 14 E119 Non-insulin-dependent diabetes
Kelas III mellitus
- without DR.
complications
ANGGILIAQ-5-44-0
STEPHANIE, SPPD
DM 0112R0830522V000361
45211593 0112R083 RJTL INT 2022 5 17 2022 5 17 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830422V000467
45245384 0112R083 RJTL INT 2022 4 20 2022 4 20 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications
SP.PD
DM 0112R0830522V000465
45245384 0112R083 RJTL INT 2022 5 19 2022 5 19 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830522V000629
45245384 0112R083 RJTL INT 2022 5 25 2022 5 25 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830222V000054
455579006 0112R083 RJTL INT 2022 2 3 2022 2 3 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830322V000027
455579006 0112R083 RJTL INT 2022 3 2 2022 3 2 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
OLLIEN
conditions
complications;I10
Q-5-44-0
KARTIKA, SP.PD
- Essential (prim
DM 0112R0830122V000506
46619735 0112R083 RJTL INT 2022 1 18 2022 1 18 E119 Non-insulin-dependent
I10 - Essential
diabetes
Kelas
(primary)
III mellitus
hypertension
without DR.
complications
OLLIENQ-5-44-0
KARTIKA, SP.PD
DM 0112R0830122V000707
46619735 0112R083 RJTL INT 2022 1 25 2022 1 25 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000065
56494412 0112R083 RJTL INT 2022 1 4 2022 1 4 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830422V000086
56494412 0112R083 RJTL INT 2022 4 5 2022 4 5 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830122V000067
58626312 0112R083 RJTL INT 2022 1 4 2022 1 4 E119 Non-insulin-dependent
I10 - Essential
diabetes
Kelas
(primary)
III mellitus
hypertension
without DR.
complications
OLLIENQ-5-44-0
KARTIKA, SP.PD
DM 0112R0830222V000121
58626312 0112R083 RJTL INT 2022 2 8 2022 2 8 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatmentdiabetes
for other
DR.mellitus
OLLIEN
conditions
without
Q-5-44-0
KARTIKA,
complications;I10
SP.PD - Es
DM 0112R0830322V000016
67145801 0112R083 RJTL INT 2022 3 2 2022 3 2 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
SYAHNIAR
conditions
complications
Q-5-44-0
MUKMINA. SP.OG
DM 0112R0830122V000106
67145801 0112R083 RJTL INT 2022 1 5 2022 1 5 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
mellitus
for other
DR.
without
OLLIEN
conditions
complications;I10
Q-5-44-0
KARTIKA, SP.PD
- Essential (prim
DM 0112R0830322V000381
75136023 0112R083 RJTL INT 2022 3 24 2022 3 24 E119 Non-insulin-dependent
I10 - Essential
diabetes
Kelas
(primary)
III mellitus
hypertension
without DR.
complications
ANGGILIAQ-5-44-0
STEPHANIE, SPPD
DM 0112R0830422V000608
75136023 0112R083 RJTL INT 2022 4 26 2022 4 26 Z098 Follow-up examination
E119 - Non-insulin-dependent
after
Kelasother
III treatment
- diabetes
for other
DR.mellitus
ANGGILIA
conditions
without
Q-5-44-0
STEPHANIE,
complications;I10
SPPD - Es
DM 0112R0830522V000353
75136023 0112R083 RJTL INT 2022 5 17 2022 5 17 Z098 Follow-up examination
E149 - Unspecified
after
Kelasother
IIIdiabetes
treatment
- mellitus
for other
DR.
without
ANGGILIA
conditions
complications
Q-5-44-0
STEPHANIE, SPPD

19
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RSUD Kebayoran Lama
jenis PRB Nosjp Nokapst Kdppklayan Nmtkp Politujsjp Day of Tgldtgsjp
Day of Tglplgsjp
Kddiagprimer
NmdiagprimerDiagsekunderKlsrawat Procedure Namadpjp Kdinacbgs
HT 0112R0830222V000099
16387762 0112R083 RJT L INT 2022 2 5 2022 2 5 E149 Unspecified I10
diabetes
- Essential
mellitus
Kelas
(primary)
without
III hypertension
complications
DR. MUHAMMAD
Q-5-44-0
PASHA
HT 0112R0830322V000061
16387762 0112R083 RJT L INT 2022 3 5 2022 3 5 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E149
for other
DR. MUHAMMAD
conditions
- Unspecified
Q-5-44-0
PASHA
diabetes mellitus
HT 0112R0830222V000238
19081725 0112R083 RJT L INT 2022 2 17 2022 2 17 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830422V000531
19081725 0112R083 RJT L INT 2022 4 22 2022 4 22 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830122V000883
298941847 0112R083 RJT L INT 2022 1 31 2022 1 31 I10 Essential (primary) hypertension
Kelas III DR. MUHAMMAD
Q-5-44-0
PASHA
HT 0112R0830322V000025
298941847 0112R083 RJT L INT 2022 3 2 2022 3 2 I10 Essential (primary) hypertension
Kelas III DR. MUHAMMAD
Q-5-44-0
PASHA
HT 0112R0830222V000206
321687596 0112R083 RJT L INT 2022 2 16 2022 2 16 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830522V000568
321687596 0112R083 RJT L INT 2022 5 24 2022 5 24 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830322V000028
327758759 0112R083 RJT L INT 2022 3 2 2022 3 2 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. MUHAMMAD
conditions
Q-5-44-0
PASHA
HT 0112R0830422V000102
327758759 0112R083 RJT L INT 2022 4 5 2022 4 5 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830522V000068
327758759 0112R083 RJT L INT 2022 5 6 2022 5 6 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830222V000339
37262660 0112R083 RJT L INT 2022 2 24 2022 2 24 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830422V000340
37262660 0112R083 RJT L INT 2022 4 14 2022 4 14 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830422V000596
37262660 0112R083 RJT L INT 2022 4 26 2022 4 26 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830222V000234
423129897 0112R083 RJT L INT 2022 2 17 2022 2 17 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830422V000591
423129897 0112R083 RJT L INT 2022 4 26 2022 4 26 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830522V000688
423129897 0112R083 RJT L INT 2022 5 27 2022 5 27 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830122V000610
423129897 0112R083 RJT L INT 2022 1 20 2022 1 20 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E149
for other
DR. ANGGILIA
conditions
- Unspecified
Q-5-44-0
STEPHANIE,
diabetes
SPPD
mellitus
HT 0112R0830122V000653
4259378 0112R083 RJT L INT 2022 1 22 2022 1 22 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. MUHAMMAD
conditions
Q-5-44-0
PASHA
HT 0112R0830222V000271
4259378 0112R083 RJT L INT 2022 2 19 2022 2 19 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. MUHAMMAD
conditions
Q-5-44-0
PASHA
HT 0112R0830522V000166
44223978 0112R083 RJT L INT 2022 5 10 2022 5 10 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
8952
hypertension;E119
- Electrocardiogram
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830322V000024
44223978 0112R083 RJT L INT 2022 3 2 2022 3 2 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E149
for other
DR. MUHAMMAD
conditions
- Unspecified
Q-5-44-0
PASHA
diabetes mellitus
HT 0112R0830122V000881
49144422 0112R083 RJT L INT 2022 1 31 2022 1 31 I10 Essential (primary)
E149 - hypertension
Unspecified
Kelas IIIdiabetes mellitusDR.
without
MUHAMMAD
complications
Q-5-44-0
PASHA
HT 0112R0830422V000134
49144422 0112R083 RJT L INT 2022 4 6 2022 4 6 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830322V000163
49550861 0112R083 RJT L INT 2022 3 15 2022 3 15 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830422V000433
49550861 0112R083 RJT L INT 2022 4 19 2022 4 19 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830422V000635
49550861 0112R083 RJT L INT 2022 4 27 2022 4 27 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830522V000635
49550861 0112R083 RJT L INT 2022 5 25 2022 5 25 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830322V000035
52031581 0112R083 RJT L INT 2022 3 2 2022 3 2 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. MUHAMMAD
conditions
Q-5-44-0
PASHA
HT 0112R0830322V000504
52031581 0112R083 RJT L INT 2022 3 30 2022 3 30 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
8749
hypertension
- Other
for other
DR.
chest
OLLIEN
conditions
x-rayQ-5-44-0
KARTIKA, SP.PD
HT 0112R0830422V000258
52031581 0112R083 RJT L INT 2022 4 12 2022 4 12 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. OLLIEN
conditions
Q-5-44-0
KARTIKA, SP.PD
HT 0112R0830422V000652
52031581 0112R083 RJT L INT 2022 4 28 2022 4 28 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
- for other
DR. OLLIEN
conditions
Q-5-44-0
KARTIKA, SP.PD
HT 0112R0830422V000614
53438919 0112R083 RJT L INT 2022 4 26 2022 4 26 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830522V000678
53438919 0112R083 RJT L INT 2022 5 27 2022 5 27 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830122V000710
55651597 0112R083 RJT L INT 2022 1 25 2022 1 25 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830422V000088
55651597 0112R083 RJT L INT 2022 4 5 2022 4 5 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830522V000222
55651597 0112R083 RJT L INT 2022 5 11 2022 5 11 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830222V000055
66665422 0112R083 RJT L INT 2022 2 3 2022 2 3 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830322V000076
66665422 0112R083 RJT L INT 2022 3 8 2022 3 8 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830222V000045
67145801 0112R083 RJT L INT 2022 2 3 2022 2 3 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830422V000083
67145801 0112R083 RJT L INT 2022 4 5 2022 4 5 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E149
for other
DR. OLLIEN
conditions
- Unspecified
Q-5-44-0
KARTIKA,diabetes
SP.PD mellitus
HT 0112R0830122V000148
68268912 0112R083 RJT L INT 2022 1 6 2022 1 6 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830222V000038
68268912 0112R083 RJT L INT 2022 2 3 2022 2 3 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830322V000020
68268912 0112R083 RJT L INT 2022 3 2 2022 3 2 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830422V000084
68268912 0112R083 RJT L INT 2022 4 5 2022 4 5 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830522V000170
68268912 0112R083 RJT L INT 2022 5 10 2022 5 10 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830122V000882
74526856 0112R083 RJT L INT 2022 1 31 2022 1 31 E149 Unspecified I10
diabetes
- Essential
mellitus
Kelas
(primary)
without
III hypertension
complications
DR. MUHAMMAD
Q-5-44-0
PASHA
HT 0112R0830322V000062
74526856 0112R083 RJT L INT 2022 3 5 2022 3 5 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. MUHAMMAD
conditions
Q-5-44-0
PASHA
HT 0112R0830422V000184
74526856 0112R083 RJT L INT 2022 4 7 2022 4 7 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
for other
DR. ANGGILIA
conditions
- Non-insulin-dependent
Q-5-44-0
STEPHANIE, SPPDdiabe
HT 0112R0830522V000410
74992658 0112R083 RJT L INT 2022 5 18 2022 5 18 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E119
- for other
DR. OLLIEN
conditions
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830522V000569
74992658 0112R083 RJT L INT 2022 5 24 2022 5 24 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
8749
hypertension;E119
- Other
for other
DR.
chest
OLLIEN
conditions
x-ray
- Non-insulin-dependent
Q-5-44-0
KARTIKA, SP.PD diabe
HT 0112R0830322V000065
74992658 0112R083 RJT L INT 2022 3 7 2022 3 7 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension;E149
for other
DR. MUHAMMAD
conditions
- Unspecified
Q-5-44-0
PASHA
diabetes mellitus
HT 0112R0830322V000324
85441595 0112R083 RJT L INT 2022 3 23 2022 3 23 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. OLLIEN
conditions
Q-5-44-0
KARTIKA, SP.PD
HT 0112R0830322V000498
85441595 0112R083 RJT L INT 2022 3 30 2022 3 30 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. OLLIEN
conditions
Q-5-44-0
KARTIKA, SP.PD
HT 0112R0830422V000131
85441595 0112R083 RJT L INT 2022 4 6 2022 4 6 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
8749
hypertension
- Other
for other
DR.
chest
OLLIEN
conditions
x-rayQ-5-44-0
KARTIKA, SP.PD
HT 0112R0830422V000338
85441595 0112R083 RJT L INT 2022 4 14 2022 4 14 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
- for other
DR. OLLIEN
conditions
Q-5-44-0
KARTIKA, SP.PD
HT 0112R0830222V000318
96963081 0112R083 RJT L INT 2022 2 23 2022 2 23 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. MUHAMMAD
conditions
Q-5-44-0
PASHA
HT 0112R0830422V000103
96963081 0112R083 RJT L INT 2022 4 5 2022 4 5 Z098 Follow-up examination
I10 - Essential
after
Kelas
(primary)
other
III treatment
hypertension
for other
DR. ANGGILIA
conditions
Q-5-44-0
STEPHANIE, SPPD

20
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RSUD Kebayoran Lama

jenis PRB Nosjp Nokapst KdppklayanNmtkp Politujsjp Day of Tgldtgsjp

Day of Tglplgsjp
Kddiagprimer
Nmdiagprimer
Diagsekunder
Klsrawat Procedure Namadpjp Kdinacbgs
asma 0112R0830322V000294
72035556 0112R083 RJTL INT 2022 3 22 2022 3 22 J459 Asthma, unspecified Kelas III 8749 - OtherDR.
chest
OLLIEN
x-rayQ-5-44-0
KARTIKA, SP
asma 0112R0830222V000278
311349873 0112R083 RJTL ANA 2022 2 21 2022 2 21 Z098 Follow-up examination
J459 - Asthma,
after
Kelasunspecified
other
III treatment for other
DR. NORMAN
conditions
Q-5-44-0
SP.A
asma 0112R0830422V000151
59332481 0112R083 RJTL ANA 2022 4 6 2022 4 6 Z098 Follow-up examination
J459 - Asthma,
after
Kelasunspecified
other
III treatment for other
DR. ANDINI
conditions
Q-5-44-0
SP.A
asma 0112R0830422V000371
54602031 0112R083 RJTL ANA 2022 4 16 2022 4 16 Z098 Follow-up examination
J459 - Asthma,
after
Kelasunspecified
other
III treatment for other
DR. NORMAN
conditions
Q-5-44-0
SP.A
asma 0112R0830322V000156
27745465 0112R083 RJTL INT 2022 3 15 2022 3 15 Z098 Follow-up examination
J459 - Asthma,
after
Kelasunspecified;E119
other
III treatment for- Non-insulin-dependent
other
DR. OLLIEN
conditions
Q-5-44-0
KARTIKA,diab
SP

jenis PRB Nosjp Nokapst KdppklayanNmtkp Politujsjp Day of Tgldtgsjp

Day of Tglplgsjp
Kddiagprimer
NmdiagprimerDiagsekunder
Klsrawat Procedure Namadpjp Kdinacbgs
epilepsi 0112R0830522V000754
413312770 0112R083 RJTL ANA 2022 5 30 2022 5 30 G409 Epilepsy, unspecified Kelas III - DR. NORMAN
Q-5-44-0
SP.A
epilepsi 0112R0830222V000354
461497464 0112R083 RJTL SAR 2022 2 25 2022 2 25 G409 Epilepsy, unspecified Kelas III DR. NADIA HUSEIN,
Q-5-44-0 SP.S
epilepsi 0112R0830322V000081
70925679 0112R083 RJTL SAR 2022 3 8 2022 3 8 Z098 Follow-up examination
G409 - Epilepsy,
after
Kelasother
unspecified
III treatment for other
DR. NADIA
conditions
HUSEIN,
Q-5-44-0 SP.S
epilepsi 0112R0830122V000683
76019220 0112R083 RJTL ANA 2022 1 24 2022 1 24 G409 Epilepsy, unspecified Kelas III DR. NORMAN
Q-5-44-0
SP.A
epilepsi 0112R0830422V000568
76019220 0112R083 RJTL ANA 2022 4 25 2022 4 25 Z098 Follow-up examination
G409 - Epilepsy,
after
Kelasother
unspecified
III treatment
- for other
DR. NORMAN
conditions
Q-5-44-0
SP.A
epilepsi 0112R0830322V000508
95388840 0112R083 RJTL ANA 2022 3 30 2022 3 30 G409 Epilepsy, unspecified Kelas III DR. NORMAN
Q-5-44-0
SP.A

jenis PRB Nosjp Nokapst KdppklayanNmtkp Politujsjp Day of Tgldtgsjp

Day of Tglplgsjp
Kddiagprimer
Nmdiagprimer
DiagsekunderKlsrawat Procedure Namadpjp Kdinacbgs
SLE 0112R0830322V000303
35935843 0112R083 RJTL INT 2022 3 22 2022 3 22 Z098 Follow-up examination
M329 - Systemic
after
Kelasother
lupus
III treatment
erythematosus,
for other
DR.unspecified
ANGGILIA
conditions
Q-5-44-0
STEPHANIE, S
SLE 0112R0830222V000070
48064133 0112R083 RJTL INT 2022 2 4 2022 2 4 Z098 Follow-up examination
M329 - Systemic
after
Kelasother
lupus
III treatment
erythematosus,
for other
DR.unspecified
ANGGILIA
conditions
Q-5-44-0
STEPHANIE, S
SLE 0112R0830122V000879
90169403 0112R083 RJTL INT 2022 1 31 2022 1 31 Z098 Follow-up examination
M329 - Systemic
after
Kelasother
lupus
III treatment
erythematosus,
for other
DR.unspecified
MUHAMMAD
conditions
Q-5-44-0
PASHA
SLE 0112R0830422V000593
90169403 0112R083 RJTL INT 2022 4 26 2022 4 26 Z098 Follow-up examination
M329 - Systemic
after
Kelasother
lupus
III treatment
erythematosus,
- for other
DR.unspecified
OLLIEN
conditions
Q-5-44-0
KARTIKA, SP.PD

21
SASARAN REKRUTMEN PRB RS dr Suyoto

PIC PRB FOKUS

PADA POLIKLINIK
INTERNA

22
SASARAN REKRUTMEN PRB RS KARTINI

PIC PRB FOKUS

PADA POLIKLINIK
ANAK??

23
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RS Kartini

24
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RS Kartini

25
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RS Kartini

26
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RS Kartini

27
Contoh kasus potensi Peserta untuk Rekrutmen PRB
RS Kartini

28
Terima Kasih

Kini Semua Ada

Dalam Genggaman!

Download Aplikasi Mobile JKN

www.bpjs-kesehatan.go.id